Ardelyx (ARDX) Misses Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Ardelyx Reports Second Quarter 2016 Financial Results
August 8, 2016 4:01 PM EDTFREMONT, Calif., Aug. 8, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2016.
"2016 continues to be a momentous year," said Mike Raab, President and Chief Executive Officer of Ardelyx. "With the completion of our recently announced $110 million private placement, we have raised net proceeds of over $190 million in 2016. Now that we have strengthened our balance sheet with sufficient capital to support the company... More
